Psychedelics research gains support from the Trump administration for treating PTSD and mental health conditions, with Veterans Affairs exploring treatments that show promise in clinical trials.

New research presented at the 2025 American Society for Clinical Oncology’s (ASCO) annual meeting has shed light on the ...

Research suggests women with high breast cancer risk and menopausal symptoms could benefit from Duavee, which reduced breast ...

With a new law that makes it easier for people to access experimental treatments, Montana could become the hub for the ...

Voyager struggles with a negative enterprise value, financial risks, and limited catalysts in a competitive Alzheimer's ...

Novocure NVCR recently announced positive top-line results from its pivotal Phase 3 PANOVA-3 trial, evaluating Tumor Treating ...

Ivarmacitinib, also known as oral SHR0302, is not yet approved by the FDA, with trials currently exploring its utility in ...

By Sammy CRABBEInfrastructure alone does not make a city great. Roads, grids, and buildings create the skeleton, but it is innovation, creativity, and collaboration that breathe life into the body. As ...

BDC-4182 Phase 1 dose-escalation study now open for enrollmentBDC-3042 Phase 1 dose-escalation data presented at AACR 2025 demonstrated a favorable safety profile, dose-dependent biological activity ...

Explore how psilocybin-assisted therapy could revolutionize treatment for Body Dysmorphic Disorder (BDD) by promoting ...

Panelists discuss how ADA recommendations emphasize treating diabetes as part of overlapping conditions requiring cardiovascular and kidney protection, moving beyond just glycemic control to ...